HER3-Targeting Antibody-Drug Conjugate Shows Encouraging Activity in Advanced Breast Cancer – OncLive

HER3-Targeting Antibody-Drug Conjugate Shows Encouraging Activity in Advanced Breast Cancer  OncLive

U3-1402, an investigational antibody-drug conjugate targeting HER3, induced objective response in more than 40% of heavily pretreated patients with …

Original published: 2018-12-06 21:24:55 Read the full Osaka News here


Some local news is curated - Original might have been posted at a different date/ time! Click the source link for details.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.